New combo therapy aims to shrink head and neck tumors
Disease control
Recruiting now
This phase 2 study tests whether adding the experimental drug VS-101 to standard chemoradiotherapy helps shrink tumors in 30 adults with head and neck cancer. Participants are randomly assigned to receive VS-101 plus chemoradiation or chemoradiation alone. The main goal is to see…
Phase: PHASE2 • Sponsor: VSPharmTech Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC